Fig. 3
From: Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumours
The comprehensive time series data on disease relapse in endocrine therapy-resistant breast cancer patients is presented with associated key molecular features—oncogenic mutations, copy-number deletion of HDAC1 and HR pathway genes, p53 signalling perturbation, etc.—contributing to genome instability (DSBR failure, telomere shortening, etc.). The molecular data was generated from the first recurrent tumour for these therapy-resistant patients. The rare germline pathogenic alterations, if present in known susceptible genes, are indicated. Created in BioRender. Ghosh, A. (2025) https://BioRender.com/i59t653.
